Definium Therapeutics (NASDAQ:DFTX) Releases Earnings Results, Beats Expectations By $0.09 EPS

Definium Therapeutics (NASDAQ:DFTX) announced its quarterly earnings data on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09, FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• DT120 delivered positive Phase III results in GAD and MDD across three studies, with rapid, durable improvements and generally good tolerability. The results earned the program FDA breakthrough therapy designations in both indications.
• Definium remains on track to file an NDA for DT120 in the first half of 2027 and is preparing for a potential launch. However, the company did not disclose details of its FDA meeting or its filing strategy for MDD, where a second Phase III study, Ascend, is still underway.
• The company reported approximately $1.05 billion in cash, equivalents, and investments at quarter-end, which it expects to fund operations into 2030. R&D and G&A expenses increased year over year as Definium expanded development and commercial-readiness efforts.
• Early DT402 results in autism spectrum disorder showed improvements across several social and functional measures, prompting the company to stop enrollment after five participants and plan a multi-day dosing study for 2027. The findings are preliminary, coming from a small, open-label study.
• Definium is developing its supervised-treatment launch infrastructure and cited payer feedback indicating a potential pricing corridor of $30,000 to $75,000. Management said more payer discussions are needed to narrow that range and emphasized that provider readiness, access, and patient support will be important to adoption.

Definium Therapeutics Trading Down 0.2%

DFTX stock traded down $0.06 during midday trading on Wednesday, hitting $34.58. The company had a trading volume of 481,791 shares, compared to its average volume of 2,211,976. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $36.39 and its 200 day moving average price is $30.14. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of -11.12 and a beta of 2.23. Definium Therapeutics has a 52 week low of $10.46 and a 52 week high of $49.70.

Insider Activity at Definium Therapeutics

In other news, insider Matthew Wiley sold 3,097 shares of the firm’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the completion of the transaction, the insider owned 359,036 shares in the company, valued at $13,129,946.52. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the transaction, the insider owned 494,228 shares of the company’s stock, valued at $18,073,917.96. The trade was a 2.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 71,098 shares of company stock worth $2,626,115. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DFTX. GAMMA Investing LLC lifted its stake in Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock worth $59,000 after acquiring an additional 343 shares during the period. Commonwealth Equity Services LLC raised its holdings in Definium Therapeutics by 4.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company’s stock worth $374,000 after purchasing an additional 382 shares during the period. Heritage Wealth Management Inc. CA raised its holdings in shares of Definium Therapeutics by 3.3% during the third quarter. Heritage Wealth Management Inc. CA now owns 12,400 shares of the company’s stock valued at $472,000 after acquiring an additional 400 shares during the last quarter. TD Waterhouse Canada Inc. boosted its position in Definium Therapeutics by 1.2% during the third quarter. TD Waterhouse Canada Inc. now owns 37,147 shares of the company’s stock worth $1,396,000 after acquiring an additional 453 shares during the last quarter. Finally, TFB Advisors LLC boosted its stake in Definium Therapeutics by 2.5% during the third quarter. TFB Advisors LLC now owns 22,064 shares of the company’s stock worth $840,000 after buying an additional 541 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on DFTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. JonesTrading boosted their price target on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. started coverage on Definium Therapeutics in a report on Friday, October 9th. They set an “overweight” rating and a $84.00 price target for the company. Canaccord Genuity Group set a $78.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 15th. Finally, Robert W. Baird raised their price target on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $66.24.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.